Centre’s approval for New oral antiviral drug approval for treating Covid

Pune: Union Health Ministry is likely to include oral antiviral drug, nirmatrelvir-ritonavir combination, in the country’s upcoming covid treatment protocol for patients with mild to moderate disease, who are at high risk of developing severe illness.

The combination drug, popularly known by the brand name paxlovid, is currently in high demand in China and a few other nations battling the Covid surge.  India’s upcoming Covid treatment protocol is expected to be released within a week. Two-tablet oral drug therapy is likely to be recommended in India for use in patients with mild to moderate Covid, who are at risk of developing severe illness, Union health ministry official told in yesterday.

Yamunanagar: Drug Smuggler Arrested With Banned Medicines Worth Lakhs Of Rupees

The World Health Organization (WHO) has strongly backed the drug in its latest Therapeutics and Covid-19 – Living Guidelines released on 13th January this year. The organisation has also clarified that the drug was safe even for pregnant and breastfeeding women.

Over the last two years, the drug has continued to show a a lot of promise in different trials world over in unvaccinated and vaccinated. It can be very useful, especially in surge scenarios in preventing hospitalization the official said. Three Indian pharmaceutical companies have already been given permission to manufacture the generic version of the new antiviral molecules.

Molnupiravir, another oral antiviral drug, has slowly fallen out of favour for its failure to show efficacy in preventing hospitalization in pepole vaccinated against Covid-19 in subsequent trials.

The country’s leading infectious diseases experts and epidemiologists have backed the nirmatrelvir-ritonavir (paxlovid) combination’s efficacy in preventing hospitalization, but have advised its careful use to prevent resistance.

Dr Anita Mathew said, In patients at high risk of progressing to severe disease  nirmatrelvir-ritonavir (Paxlovid) has demonstrated good clinical benefit. But the medication has significant interaction with some other medications and should be taken only if recommended by a physician.

Related Posts

  • Pharma
  • July 13, 2024
  • 101 views
Telangana DCA Seizes Overpriced Anti-Cancer Medicine In Karimnagar

Hyderabad: Drugs Control Administration officials seized ‘Dacazee 500 Injection’ (Dacarbazine Injection IP 500 mg), during the raids carried out on 11th and 12th July, 2024, at a medical shop located in…

  • Pharma
  • July 13, 2024
  • 82 views
Drug Price Regulation Leads To Decline In Availability Of Essential Medicines, Study Finds

Kolkata: The Drug Price Control Order (DPCO) 2013, India’s key drug regulation aimed at making essential medicines more affordable, has inadvertently led to a decline in the availability of these…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Telangana DCA Seizes Overpriced Anti-Cancer Medicine In Karimnagar

Telangana DCA Seizes Overpriced Anti-Cancer Medicine In Karimnagar

Drug Price Regulation Leads To Decline In Availability Of Essential Medicines, Study Finds

Drug Price Regulation Leads To Decline In Availability Of Essential Medicines, Study Finds

EMA Warns Of Anaphylactic Reactions To MS Drug

EMA Warns Of Anaphylactic Reactions To MS Drug

14 Barred Patanjali Products Sold Across Counter At Dedicated Stores

14 Barred Patanjali Products Sold Across Counter At Dedicated Stores

Mumbai: FDA Conducts Raids At Three Different Locations In Vasai, Seized Ayurvedic Drugs Worth Rs 1.41 Crore

Mumbai: FDA Conducts Raids At Three Different Locations In Vasai, Seized Ayurvedic Drugs Worth Rs 1.41 Crore

Telangana DCA Raids 2 Places, Seizes Illegally Stocked And Overpriced Medicines

Telangana DCA Raids 2 Places, Seizes Illegally Stocked And Overpriced Medicines